SBSergey G. Bolotin

Sergey G. Bolotin

*This is an algorithmically generated author record based on publicly available information.

Sergey G. Bolotin has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk factors associated with mortality in patients with multiple myeloma

    by S. G. Bolotin, A. V. Solovieva, A. S. Pristupa, N. V. Sergeeva

    Introduction. According to foreign authors some laboratory markers and comorbidity are independent predictors of death in multiple myeloma (MM).Aim. To identify risk factors associated with mortality in patients with MM.Materials and methods. A retrospective analysis of 149 medical records of patients of the hematology department of the Regional Clinical Hospital with a diagnosis of multiple myeloma was carried out. The patients are divided into two groups depending on the clinical outcome: the 1st group includes 90 living patients; the 2nd group includes 59 patients whose death occurred in the hospital during the period from 2010–2019. Of the 149 patients: 87 women (58%), 62 men (42%). The mean age of the patients was 65.7 ± 8.7 years. The clinical, demographic and laboratory indicators of the groups were analyzed, and comorbidity was assessed using the Charlson index.Results. In the 1st group of patients, there were 35 men (39%) and 55 women (61%). The ratio of men to women is 1:1.6. The mean age in this group is 67 ± 9.1 years. The 2nd group is represented by 27 (46%) men, 32 (54%) women. The mean age was 63.7 ± 7.6 years. In the 1st group of patients, all patients were diagnosed with stage III disease, with most patients in the subgroup associated with renal dysfunction (p = 0.002). Anaemia and markers of renal damage were more frequent in the group of deceased patients (p < 0.001, p = 0.002, respectively). Comparative analysis of laboratory indicators showed that in the haemogram of the group of living patients, the level of erythrocytes, haemoglobin, platelets was significantly higher than in group 2 (p < 0.05); the level of creatinine, urea was 1.8 times higher in the group of deceased patients than in the group of living patients (p < 0.05). Chronic heart failure was statistically significantly more common in the deceased group than in the living group (22% vs. 7.8%, p = 0.025). The incidence of pneumonia was higher in the deceased group than in the 1st group (p < 0.001).Conclusion. Risk factors associated with mortality include manifestations of MM such as anaemia, thrombocytopenia, renal dysfunction and late diagnosis at stage III of the disease. Chronic heart failure, as a complication of cardiovascular disease, is a risk factor for adverse outcome. Comorbidity, infectious diseases (pneumonia) are associated with a worse prognosis, probably due to poorer tolerability of standard therapy.

  • Analysis of Recorded Morbidity, Prevalence and Hospital Mortality of Patients with Symptomatic Multiple Myeloma in the Ryazan Region for 10 Years

    by Sergey G. Bolotin, Mariya S. Zenina, Aleksandra V. Solov’yEva, Alexandr S. Pristupa

    INTRODUCTION: Multiple myeloma (MM) is a disease whose substrate is plasma cells; it is characterized by the production of monoclonal immunoglobulin. Epidemiology of MM in Russia is insufficiently studied. Of interest is a study of dynamics of the main epidemiological parameters of multiple myeloma in the context of a poor epidemiological prognosis for oncological diseases in the Russian Federation and in the world in general. AIM: To analyze the main epidemiological parameters of symptomatic MM in the Ryazan region for 10 years (20102019). MATERIALS AND METHODS: A total of 343 medical records of patients with symptomatic MM were analyzed, of them 146 men (age median 65 years), 197 women (age median 64 years). The patients underwent inpatient treatment in the hematology and chemotherapy department of Ryazan Regional Clinical Hospital from 2010 to 2019. The epidemiological analysis consisted in evaluation of the parameters of the registered morbidity, prevalence and hospital mortality. The criterion for inclusion in the study was the existence of symptomatic MM in the patient. For statistical processing, Microsoft information and analytical system, Office package was used. RESULTS: The highest amount of new cases of MM were identified in 2018 (4.19 per 100,000 population), the lowest in 2012 (1.83 per 100,000 population). In the analyzed period, the number of cases of newly diagnosed MM per year increased by 30.3%. Most patients at the time of diagnosis were in the age group of 6069 years. Morbidity with MM in the age group of 3049 years was comparable in men and women, however, among the patients 50 years women predominated. Over 10 years, the index of MM prevalence in the Ryazan region increased 1.43 times: from 6.71 to 9.6 per 100,000 population, index of hospital mortality from 1.4% to 3.3%. CONCLUSION: The growth of the registered mortality and prevalence of MM in the Ryazan region in 20102019 was identified, which corresponds to the dynamics in other regions of the Russian Federation. Also, during the analyzed period, an increase in hospital mortality of patients with MM was observed in the region.